Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Infliximab (IFX) is potentially immunogenic, causing anti-infliximab antibodies that may interfere with the clinical efficacy and safety of the drug. There is an industry in measuring these antibodies, but the technicalities are legion, association with response poor and if they affect pharmacokinetics, it is by influencing drug levels. In contrast, IFX levels are associated with clinical response. So why make it complex? In this paper, we evaluate studies reporting the incidence of IFX antibodies in IBD, their impact on efficacy, safety and pharmacokinetics of IFX.


Journal article


Practical Gastroenterology

Publication Date





11 - 20